Published in Gut on June 01, 2001
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest (2004) 2.52
Cannabinoid hyperemesis relieved by compulsive bathing. Mayo Clin Proc (2009) 1.98
Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev (2011) 1.75
Cannabinoid hyperemesis syndrome: clinical diagnosis of an underrecognised manifestation of chronic cannabis abuse. World J Gastroenterol (2009) 1.74
Cannabinoids as novel anti-inflammatory drugs. Future Med Chem (2009) 1.58
Effects of cannabinoid receptor agonists on rat gastric acid secretion: discrepancy between in vitro and in vivo data. Dig Dis Sci (2006) 1.44
Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol (2007) 1.29
Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS One (2009) 1.16
Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol (2003) 1.15
The cannabis hyperemesis syndrome characterized by persistent nausea and vomiting, abdominal pain, and compulsive bathing associated with chronic marijuana use: a report of eight cases in the United States. Dig Dis Sci (2010) 1.15
The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo. Br J Pharmacol (2007) 1.13
Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol (2011) 1.10
Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol (2008) 1.10
Sustained weight loss after Roux-en-Y gastric bypass is characterized by down regulation of endocannabinoids and mitochondrial function. Ann Surg (2008) 1.09
FAAH deficiency promotes energy storage and enhances the motivation for food. Int J Obes (Lond) (2009) 1.05
Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J Physiol (2003) 1.03
Main ion channels and receptors associated with visceral hypersensitivity in irritable bowel syndrome. Ann Gastroenterol (2014) 1.02
Cannabinoid-induced hyperphagia: correlation with inhibition of proopiomelanocortin neurons? Physiol Behav (2007) 1.02
Involvement of cannabinoid receptors in gut motility and visceral perception. Br J Pharmacol (2004) 0.99
Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. Br J Pharmacol (2010) 0.99
Compulsive showering and marijuana use - the cannabis hyperemisis syndrome. Am J Case Rep (2013) 0.99
Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. Br J Pharmacol (2002) 0.98
Investigation on the relationship between cannabinoid CB1 and opioid receptors in gastrointestinal motility in mice. Br J Pharmacol (2006) 0.97
Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon. Br J Pharmacol (2006) 0.93
Antispasmodic and antidiarrhoeal activities of 6-(4-hydroxy-3-methoxyphenyl)-hexanonic acid from Pycnocycla spinosa Decne. exBoiss. Res Pharm Sci (2015) 0.92
Modulation of gut-specific mechanisms by chronic δ(9)-tetrahydrocannabinol administration in male rhesus macaques infected with simian immunodeficiency virus: a systems biology analysis. AIDS Res Hum Retroviruses (2014) 0.92
Extraordinary cause of acute gastric dilatation and hepatic portal venous gas: Chronic use of synthetic cannabinoid. World J Gastroenterol (2015) 0.90
Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. Gut (2006) 0.89
Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases. Can J Gastroenterol (2011) 0.85
Tolerance to cannabinoid response on the myenteric plexus of guinea-pig ileum and human small intestinal strips. Br J Pharmacol (2006) 0.83
Medicinal plants used by the Tamang community in the Makawanpur district of central Nepal. J Ethnobiol Ethnomed (2014) 0.82
Cannabinoid CB1 receptors are expressed by parietal cells of the human gastric mucosa. J Histochem Cytochem (2008) 0.82
Plasticity of mouse enteric synapses mediated through endocannabinoid and purinergic signaling. Neurogastroenterol Motil (2012) 0.82
The anti-nausea effects of CB1 agonists are mediated by an action at the visceral insular cortex. Br J Pharmacol (2012) 0.81
Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation. Curr Neuropharmacol (2016) 0.80
Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation. Br J Pharmacol (2015) 0.80
Monoglyceride lipase deficiency causes desensitization of intestinal cannabinoid receptor type 1 and increased colonic μ-opioid receptor sensitivity. Br J Pharmacol (2015) 0.79
AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner. Br J Pharmacol (2015) 0.78
In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat. Neurogastroenterol Motil (2015) 0.77
The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease. Neurogastroenterol Motil (2016) 0.77
Acute Δ(9)-tetrahydrocannabinol blocks gastric hemorrhages induced by the nonsteroidal anti-inflammatory drug diclofenac sodium in mice. Eur J Pharmacol (2013) 0.77
Pharmacological characterization of cannabinoid receptor activity in the rat-isolated ileum myenteric plexus-longitudinal muscle preparation. Br J Pharmacol (2010) 0.76
Cannabinoid hyperemesis. BMJ Case Rep (2010) 0.76
A diet containing a nonfat dry milk matrix significantly alters systemic oxylipins and the endocannabinoid 2-arachidonoylglycerol (2-AG) in diet-induced obese mice. Nutr Metab (Lond) (2014) 0.76
Constitutive activity at the cannabinoid CB(1) receptor and behavioral responses. Methods Enzymol (2010) 0.76
Tricyclic Pyrazoles. Part 5. Novel 1,4-Dihydroindeno[1,2-c]pyrazole CB2 Ligands Using Molecular Hybridization Based on Scaffold Hopping. Open Med Chem J (2012) 0.75
Molecules Acting on CB1 Receptor and their Effects on Morphine Withdrawal In Vitro. Open Biochem J (2009) 0.75
Role of principal ionotropic and metabotropic receptors in visceral pain. J Neurogastroenterol Motil (2015) 0.75
Interactions of Cannabinoids With Biochemical Substrates. Subst Abuse (2017) 0.75
Electroacupuncture at LI11 promotes jejunal motility via the parasympathetic pathway. BMC Complement Altern Med (2017) 0.75
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett (1994) 5.30
Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther (1997) 5.20
Preliminary experiments on the chemistry and pharmacology of cannabis. Nature (1970) 3.41
Pharmacology of cannabinoid receptor ligands. Curr Med Chem (1999) 2.34
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A (1999) 2.32
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci (1998) 2.18
Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J Biol Chem (1995) 1.98
Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol (1997) 1.61
An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem (1995) 1.54
Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci U S A (1999) 1.51
The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol (2000) 1.50
Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmacol Ther (1999) 1.44
Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol (1992) 1.44
Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Br J Pharmacol (1996) 1.40
Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther (1994) 1.33
Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors. Br J Pharmacol (1998) 1.31
Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin Investig Drugs (2000) 1.30
Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat. Neuroscience (1998) 1.28
Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol (1997) 1.26
Inhibitory effect of cannabinoid agonists on gastric emptying in the rat. Naunyn Schmiedebergs Arch Pharmacol (1999) 1.23
In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol (1998) 1.18
Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. Eur J Pharmacol (1995) 1.17
The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur J Pharmacol (1999) 1.13
Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors. Eur J Pharmacol (1999) 1.13
Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol (1999) 1.13
Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther (1989) 1.13
Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. Br J Pharmacol (2000) 1.07
Cannabis, hypochlorhydria, and cholera. Lancet (1978) 1.05
Cannabinoid modulation of intestinal propulsion in mice. Eur J Pharmacol (1998) 1.05
Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways. Neuropharmacology (1999) 1.01
The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther (1988) 1.01
Correlation between the in vivo and an in vitro expression of opiate withdrawal precipitated by naloxone: their antagonism by l-(-)-delta9-tetrahydrocannabinol. J Pharmacol Exp Ther (1976) 1.01
SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats. Behav Pharmacol (1999) 1.01
Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine. Br J Pharmacol (1998) 0.99
Modulation of peristalsis by cannabinoid CB(1) ligands in the isolated guinea-pig ileum. Br J Pharmacol (2000) 0.99
Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochim Biophys Acta (1997) 0.99
High-affinity cannabinoid binding sites in brain membranes labeled with [3H]-5'-trimethylammonium delta 8-tetrahydrocannabinol. J Pharmacol Exp Ther (1985) 0.99
Effects of cannabinoid receptor ligands on electrophysiological properties of myenteric neurones of the guinea-pig ileum. Br J Pharmacol (1997) 0.98
Stereospecific presynaptic inhibitory effect of delta9-tetrahydrocannabinol on cholinergic transmission in the myenteric plexus of the guinea pig. Can J Physiol Pharmacol (1978) 0.98
Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat. Naunyn Schmiedebergs Arch Pharmacol (1999) 0.97
Tolerance to the effect of delta9-tetrahydrocannabinol in mice on intestinal motility, temperature and locomotor activity. Psychopharmacologia (1975) 0.95
Some pharmacological effects of two tetrahydrocannabinols. J Pharmacol Exp Ther (1962) 0.93
The effect of cannabinoids on intestinal motility and their antinociceptive effect in mice. Br J Pharmacol (1973) 0.92
Effects of SR 141716A after acute or chronic cannabinoid administration in dogs. Eur J Pharmacol (1998) 0.91
Effects of acute and chronic administration of cannabis sativa and (-) delta9-trans-tetrahydrocannabinol on the behavior of rats in an open-field arena. Psychopharmacologia (1971) 0.91
Some pharmacological and toxicological effects of 1-trans- 8 and 1-trans- 9 -tetrahydrocannabinol in laboratory rodents. Arch Int Pharmacodyn Ther (1972) 0.90
Cross-tolerance and convergent dependence between morphine and cannabimimetic agent WIN 55,212-2 in the guinea-pig ileum myenteric plexus. Eur J Pharmacol (1999) 0.88
Anandamide amidohydrolase (fatty acid amide hydrolase). Prostaglandins Other Lipid Mediat (2000) 0.88
Effect of 9 -THC on the open-field activity of the rat. Psychopharmacologia (1972) 0.88
Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol. Science (1975) 0.86
Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine. Br J Pharmacol (2000) 0.86
The interaction between prostaglandin E1 and delta 9-tetrahydrocannabinol on intestinal motility and on the abdominal constriction response in the mouse. Psychopharmacologia (1976) 0.84
Evaluation of antiulcer activity of delta9-tetrahydrocannabinol in the Shay rat test. Pharmacology (1978) 0.81
Evidence that cannabinoid-induced inhibition of electrically evoked contractions of the myenteric plexus--longitudinal muscle preparation of guinea-pig small intestine can be modulated by Ca2+ and cAMP. Can J Physiol Pharmacol (1998) 0.81
An investigation of the involvement of GABA in certain pharmacological effects of delta-9-tetrahydrocannabinol. Pharmacol Biochem Behav (1991) 0.80
Inhibition of histamine-stimulated gastric acid secretion by delta 9-tetrahydrocannabinol in rat isolated stomach. Eur J Pharmacol (1980) 0.80
Interaction of delta9-tetrahydrocannabinol and cannabidiol on intestinal motility in mice. J Pharm Pharmacol (1974) 0.79
Delta-9-tetrahydrocannabinol and gastric emptying. Br J Clin Pharmacol (1983) 0.78
SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists. Zhongguo Yao Li Xue Bao (1999) 0.78
Pravadoline: profile in isolated tissue preparations. J Pharmacol Exp Ther (1990) 0.77
Effects of 7-hydroxy-delta-6-tetrahydrocannabinol and some related cannabinoids on the guinea pig isolated ileum. Acta Physiol Scand (1975) 0.77